Product logins

Find logins to all Clarivate products below.


In 2017, branded biologic sales in oncology, immunology, endocrinology, and nephrology across the major markets exceeded $80 billion. Sales from biosimilars in the
same therapy areas and regions totaled approximately $2.5 billion. Throughout our 2017-2027 forecast period, increasing numbers of branded biologics are set to lose 
patent protection, with biosimilars expected to enter the market and erode both patient share and drug prices. We present our forecasts for key reference brands and
their biosimilars by therapeutic area, molecule, and region.

Related Market Assessment Reports

Report
Biosimilars – Access & Reimbursement – Payer Insights Landscape (US/EU)
Biosimilar regulations and guidance have been defined, at least in draft form, in most the world’s leading pharmaceutical markets. In many cases, biosimilar guidance is based on that of the EMA,…
Report
Biosimilars – Access & Reimbursement – Access & Reimbursement Global Landscape
The regulatory and market access landscape for biosimilars is constantly evolving. For a company seeking to develop a biosimilar for multiple markets, keeping track of the similarities and…
Report
Biosimilars – Emerging Biosimilars – Emerging Biosimilars Landscape
The Emerging Biosimilars Landscape offers extensive coverage of the global biosimilars development landscape. We track over 719 currently available and novel biosimilar products, detailing…
Report
Biosimilars – Forecast – Ophthalmology
In 2023, sales of branded biologics in ophthalmology exceeded $9.8 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2023-2033 forecast period…
Report
Biosimilars – Forecast – Respiratory
In 2023, sales of branded biologics for respiratory indications totaled about $6.6 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2023-2033…